Clear Street lowered the firm’s price target on Sagimet Biosciences (SGMT) to $28 from $37 and keeps a Buy rating on the shares. The firm is adjusting its model following the company’s recent strategic shift to focus on acne vs. MASH, with a planned phase 3 initiation of denifanstat in moderate to severe acne expected in the second half of FY26, the analyst tells investors in a research note.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SGMT:
- Sagimet Maintained at Buy as Strong Cash Runway and Advancing Acne Franchise Support Unchanged $28 Price Target
- Sagimet Biosciences reports Q1 EPS (33c), consensus (35c)
- Sagimet Biosciences price target raised to $49 from $28 at Canaccord
- Sagimet Biosciences price target raised to $33 from $28 at Oppenheimer
- Sagimet Therapeutics: Buy Rating Reiterated on Denifanstat’s First-Line Acne Potential; $28 Price Target Unchanged